Trial Profile
Phase II Clinical Trial With the Combination Gemcitabine, Oxaliplatin and Vinorelbine as First Line Treatment in Patients With Non-Small Cell Bronchopulmonary Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Vinorelbine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms GON
- Sponsors Sanofi
- 27 Aug 2007 Status change from in progress to completed.
- 12 Sep 2006 New trial record.